{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:52:47Z","timestamp":1791064367730,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12833-4","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:02:09Z","timestamp":1790593329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance, a narrative review"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-1171","authenticated-orcid":false,"given":"Miguel","family":"Borreg\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Asunci\u00f3n","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-2497","authenticated-orcid":false,"given":"Javier-David","family":"Ben\u00edtez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"5151","key":"12833_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science 263(5151):1281\u20131284. https:\/\/doi.org\/10.1126\/science.8122112","journal-title":"Science"},{"issue":"10","key":"12833_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3580","volume":"13","author":"B Hallberg","year":"2013","unstructured":"Hallberg B, Palmer RH (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 13(10):685\u2013700. https:\/\/doi.org\/10.1038\/nrc3580","journal-title":"Nat Rev Cancer"},{"key":"12833_CR3","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.09811","volume":"4","author":"J Guan","year":"2015","unstructured":"Guan J, Umapathy G, Yamazaki Y et al (2015) FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. eLife 4:e09811. https:\/\/doi.org\/10.7554\/eLife.09811","journal-title":"eLife"},{"issue":"52","key":"12833_CR4","doi-asserted-by":"publisher","first-page":"15862","DOI":"10.1073\/pnas.1520099112","volume":"112","author":"AV Reshetnyak","year":"2015","unstructured":"Reshetnyak AV, Murray PB, Shi X et al (2015) Augmentor alpha and beta (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci U S A 112(52):15862\u201315867. https:\/\/doi.org\/10.1073\/pnas.1520099112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 24","key":"12833_CR5","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1242\/jcs.02695","volume":"118","author":"JY Gouzi","year":"2005","unstructured":"Gouzi JY, Moog-Lutz C, Vigny M, Brunet-de Carvalho N (2005) Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells. J Cell Sci 118(Pt 24):5811\u20135823. https:\/\/doi.org\/10.1242\/jcs.02695","journal-title":"J Cell Sci"},{"issue":"7153","key":"12833_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561\u2013566. https:\/\/doi.org\/10.1038\/nature05945","journal-title":"Nature"},{"issue":"9","key":"12833_CR7","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","volume":"15","author":"K Takeuchi","year":"2009","unstructured":"Takeuchi K, Choi YL, Togashi Y et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15(9):3143\u20133149. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3248","journal-title":"Clin Cancer Res"},{"issue":"12","key":"12833_CR8","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1002\/cncr.25843","volume":"117","author":"DW Wong","year":"2011","unstructured":"Wong DW, Leung EL, Wong SK et al (2011) A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 117(12):2709\u20132718. https:\/\/doi.org\/10.1002\/cncr.25843","journal-title":"Cancer"},{"issue":"2","key":"12833_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood.2021013338","volume":"139","author":"PG Kemps","year":"2022","unstructured":"Kemps PG, Picarsic J, Durham BH et al (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139(2):256\u2013280. https:\/\/doi.org\/10.1182\/blood.2021013338","journal-title":"Blood"},{"issue":"1","key":"12833_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0002-9440(10)62966-5","volume":"167","author":"Y Osajima-Hakomori","year":"2005","unstructured":"Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R (2005) Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167(1):213\u2013222. https:\/\/doi.org\/10.1016\/S0002-9440(10)62966-5","journal-title":"Am J Pathol"},{"issue":"1","key":"12833_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/JTO.0b013e3181fb7cd6","volume":"6","author":"M Salido","year":"2011","unstructured":"Salido M, Pijuan L, Martinez-Aviles L et al (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 6(1):21\u201327","journal-title":"J Thorac Oncol"},{"issue":"2","key":"12833_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yexmp.2013.06.002","volume":"95","author":"M Wang","year":"2013","unstructured":"Wang M, Zhou C, Sun Q et al (2013) ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Exp Mol Pathol 95(2):124\u2013130. https:\/\/doi.org\/10.1016\/j.yexmp.2013.06.002","journal-title":"Exp Mol Pathol"},{"issue":"8","key":"12833_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.ejca.2013.02.005","volume":"49","author":"SF Schoppmann","year":"2013","unstructured":"Schoppmann SF, Streubel B, Birner P (2013) Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. Eur J Cancer 49(8):1876\u20131881. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.005","journal-title":"Eur J Cancer"},{"issue":"10","key":"12833_CR14","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1038\/bjc.2013.641","volume":"109","author":"P Bavi","year":"2013","unstructured":"Bavi P, Jehan Z, Bu R et al (2013) ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer 109(10):2735\u20132743. https:\/\/doi.org\/10.1038\/bjc.2013.641","journal-title":"Br J Cancer"},{"key":"12833_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13058-015-0610-3","volume":"17","author":"AK Siraj","year":"2015","unstructured":"Siraj AK, Beg S, Jehan Z et al (2015) ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res 17:127. https:\/\/doi.org\/10.1186\/s13058-015-0610-3","journal-title":"Breast Cancer Res"},{"issue":"3","key":"12833_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41379-019-0323-8","volume":"33","author":"F Le Loarer","year":"2020","unstructured":"Le Loarer F, Cleven AHG, Bouvier C et al (2020) A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol 33(3):404\u2013419. https:\/\/doi.org\/10.1038\/s41379-019-0323-8","journal-title":"Mod Pathol"},{"issue":"1","key":"12833_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/PAS.0000000000001103","volume":"43","author":"AL Cheah","year":"2019","unstructured":"Cheah AL, Zou Y, Lanigan C et al (2019) ALK expression in angiomatoid fibrous histiocytoma: a potential diagnostic pitfall. Am J Surg Pathol 43(1):93\u2013101. https:\/\/doi.org\/10.1097\/PAS.0000000000001103","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"12833_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13000-023-01383-z","volume":"18","author":"XY Zhang","year":"2023","unstructured":"Zhang XY, Li J, Chen SL, Li Y, Wang H, He JH (2023) Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report. Diagn Pathol 18(1):97. https:\/\/doi.org\/10.1186\/s13000-023-01383-z","journal-title":"Diagn Pathol"},{"issue":"6","key":"12833_CR19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.cell.2019.08.018","volume":"178","author":"D Demircioglu","year":"2019","unstructured":"Demircioglu D, Cukuroglu E, Kindermans M et al (2019) A pan-cancer transcriptome analysis reveals pervasive regulation through alternative promoters. Cell 178(6):1465\u20131477e17. https:\/\/doi.org\/10.1016\/j.cell.2019.08.018","journal-title":"Cell"},{"issue":"28","key":"12833_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl5606","volume":"10","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Chen Y, Zou X et al (2024) Pan-cancer transcriptome analysis reveals widespread regulation through alternative tandem transcription initiation. Sci Adv 10(28):eadl5606. https:\/\/doi.org\/10.1126\/sciadv.adl5606","journal-title":"Sci Adv"},{"issue":"7573","key":"12833_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature15258","volume":"526","author":"T Wiesner","year":"2015","unstructured":"Wiesner T, Lee W, Obenauf AC et al (2015) Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 526(7573):453\u2013457. https:\/\/doi.org\/10.1038\/nature15258","journal-title":"Nature"},{"issue":"11","key":"12833_CR22","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1248\/bpb.b17-00548","volume":"40","author":"Y Takakura","year":"2017","unstructured":"Takakura Y, Yamaguchi N, Honda T et al (2017) The truncated isoform of the receptor tyrosine kinase ALK generated by alternative transcription initiation (ALKATI) induces chromatin structural changes in the nucleus in a kinase activity-dependent manner. Biol Pharm Bull 40(11):1968\u20131975. https:\/\/doi.org\/10.1248\/bpb.b17-00548","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"12833_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41388-019-0973-5","volume":"39","author":"BS Xu","year":"2020","unstructured":"Xu BS, Chen HY, Que Y, Xiao W, Zeng MS, Zhang X (2020) ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma. Oncogene 39(1):151\u2013163. https:\/\/doi.org\/10.1038\/s41388-019-0973-5","journal-title":"Oncogene"},{"issue":"8","key":"12833_CR24","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/mc.23928","volume":"64","author":"A Yokoi","year":"2025","unstructured":"Yokoi A, Yoshimori D, Oguri Y, Hashimura M, Saegusa M (2025) A transcriptional variant of anaplastic lymphoma kinase promotes apoptosis in ovarian high-grade serous carcinoma. Mol Carcinog 64(8):1283\u20131288. https:\/\/doi.org\/10.1002\/mc.23928","journal-title":"Mol Carcinog"},{"issue":"11","key":"12833_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103343","volume":"24","author":"H Inam","year":"2021","unstructured":"Inam H, Sokirniy I, Rao Y et al (2021) Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors. iScience 24(11):103343. https:\/\/doi.org\/10.1016\/j.isci.2021.103343","journal-title":"iScience"},{"issue":"1","key":"12833_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/1535-7163.MCT-17-0472","volume":"17","author":"KL Couts","year":"2018","unstructured":"Couts KL, Bemis J, Turner JA et al (2018) ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms. Mol Cancer Ther 17(1):222\u2013231. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0472","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"12833_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/his.14191","volume":"77","author":"KK Shah","year":"2020","unstructured":"Shah KK, Neff JL, Erickson LA et al (2020) Correlation of novel ALKATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology 77(4):601\u2013610. https:\/\/doi.org\/10.1111\/his.14191","journal-title":"Histopathology"},{"issue":"6","key":"12833_CR28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/PAS.0000000000000611","volume":"40","author":"KJ Busam","year":"2016","unstructured":"Busam KJ, Vilain RE, Lum T et al (2016) Primary and metastatic cutaneous melanomas express ALK through alternative transcriptional initiation. Am J Surg Pathol 40(6):786\u2013795","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"12833_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3760\/cma.j.cn112151-20251007-00662","volume":"55","author":"Z Chen","year":"2026","unstructured":"Chen Z, Yang HJ, Cao H, Xu LM, Teng XD (2026) Malignant melanoma with anaplastic lymphoma kinase positivity: a clinicopathological analysis of three cases. Zhonghua Bing Li Xue Za Zhi 55(1):28\u201333. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20251007-00662","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"5","key":"12833_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jtho.2018.12.003","volume":"14","author":"JC Chang","year":"2019","unstructured":"Chang JC, Zhang L, Drilon AE et al (2019) Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements. J Thorac Oncol 14(5):825\u2013834. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.003","journal-title":"J Thorac Oncol"},{"key":"12833_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cup.70171","author":"H Reboul","year":"2026","unstructured":"Reboul H, Thibaut I, Galinier P et al (2026) A PRKCA-fused blue melanocytoma expressing a truncated ALK isoform. J Cutan Pathol. https:\/\/doi.org\/10.1111\/cup.70171","journal-title":"J Cutan Pathol"},{"issue":"2","key":"12833_CR32","doi-asserted-by":"publisher","first-page":"100956","DOI":"10.1016\/j.modpat.2025.100956","volume":"39","author":"Z Helias-Rodzewicz","year":"2026","unstructured":"Helias-Rodzewicz Z, Ungureanu IA, Kemps PG et al (2026) ALKATI drives nuclear anaplastic lymphoma kinase expression in histiocytic neoplasms without ALK fusions. Mod Pathol 39(2):100956. https:\/\/doi.org\/10.1016\/j.modpat.2025.100956","journal-title":"Mod Pathol"},{"issue":"3","key":"12833_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Arch Pathol Lab Med 142(3):321\u2013346. https:\/\/doi.org\/10.5858\/arpa.2017-0388-CP","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"12833_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","volume":"20","author":"M Pekar-Zlotin","year":"2015","unstructured":"Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L et al (2015) Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 20(3):316\u2013322","journal-title":"Oncologist"},{"issue":"4","key":"12833_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jmoldx.2014.03.006","volume":"16","author":"HJ Abel","year":"2014","unstructured":"Abel HJ, Al-Kateb H, Cottrell CE et al (2014) Detection of gene rearrangements in targeted clinical next-generation sequencing. J Mol Diagn 16(4):405\u2013417","journal-title":"J Mol Diagn"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12833-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12833-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12833-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:23Z","timestamp":1791061343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12833-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12833"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12833-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This narrative review did not involve new research with human participants or animals.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1657"}}